Navigation Links
Newly Released Canadian Data Links Vaccines with Pervasive,Developmental Disorder

National Autism Association calls 2006 Pediatrics study fatally flawed

CHICAGO, March 07, 2007 /PRNewswire-USNewswire/ -- New findings presented yesterday at a National Autism Association meeting bolster claims that vaccines may play a role in the development of autism spectrum disorders. David Ayoub, MD presented data suggesting a correlation between mercury- containing vaccines and rates of pervasive developmental disorder (PDD), a form of autism, in Montreal. The peak rate of one in 87 children diagnosed with PDD occurred following the period of greatest exposure to the mercury- based vaccine preservative thimerosal. A flattening of the rates studied is now emerging as mercury-containing vaccines have been gradually eliminated from the routine schedule.

This new data points out flaws in a 2006 study published in the journal Pediatrics by Eric Fombonne, MD, et al, which found PDD rates continued to increase even when rates of MMR vaccination and use of mercury-containing vaccines decreased. The study population consisted of a single Montreal school board that was an Autism Center of Excellence, suggesting an over- ascertainment of regional diagnoses. Dr. Ayoub and co-authors Monica Ruscitti, BA, and F. Edward Yazbak, MD broadened the data to include all five Montreal school boards.

The earlier study also reported PDD rates in children from Montreal, but MMR coverage data was taken from Quebec City located 265km from Montreal. The researchers confirmed MMR coverage rates actually increased in Montreal along with PDD, noting a sharper rise in rates after the number of required MMR shots doubled.

The Pediatrics paper claimed there was no exposure to mercury from vaccines post-1996 although several mercury-containing vaccines were administered well beyond 1996. "It's irresponsible that such flawed data was published in a medical journal. This new information confirms a relationship between va ccines and autism that can't be explained by better diagnosing or changing diagnostic criteria," said Karen McDonough, NAA -- Chicago president.

Drs. Ayoub and Yazbak detailed the Fombonne study flaws in letters to Pediatrics which the journal declined to publish. Editor Jerold F. Lucey, MD stated in a reply, "I believe the evidence of no link between MMR and Autism is sufficient. It's not worth publishing more on this subject."

"This dismissal of legitimate concerns regarding data affecting those suffering with autism is a disgrace," commented Ms. McDonough.

     For more information:  www.nationalautism.org


     Contacts:  Wendy Fournier 401-632-7523

                Rita Shreffler 417-818-9030

CONTACT: Wendy Fournier, +1-401-632-7523, or Rita Shreffler,+1-417-818-9030, both of National Autism Association

Web site: http://www.nationalautism.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... YORK , Feb. 23, 2017 /PRNewswire/ ... comprehensive insights on the various drugs being ... report covers all the drugs that are ... & Clinical). The pipeline focuses on novel ... molecules, antibodies, stem cell therapies, recombinant proteins ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) today announced ... Directors that will be submitted to the 2017 Annual ... the company,s three largest shareholders at the end of ... seat on the Nomination Committee, and the Chairman of ... was as follows:  Anders ...
Breaking Medicine Technology:
(Date:2/23/2017)... Boston, MA (PRWEB) , ... February 23, 2017 ... ... Education and Department of Justice jointly issued a letter to withdraw ... in accordance with their gender identity. The guidance issued in May 2016 by ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Development will host a diverse symposium on “Doping in Sport: How ... and Sheppard Mullin Richter & Hampton LLP. The symposium will be held at ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, ... trials, today announced that Premier Research, a leading clinical development service provider, has ... are becoming increasingly complex, due in part to an array of circumstances including ...
Breaking Medicine News(10 mins):